Reproductive health · Decision
ALFI v. Garin: contraceptive certification and due process
The FDA had not meaningfully addressed objections to contraceptive certification. The Court required an opportunity to present scientific evidence; its later resolution clarified the hearing, appeal route, and conditional restraint.
Contested contraceptive certification required a genuine opportunity to present and have scientific evidence considered. The FDA retained the scientific task, and a courtroom-style trial was unnecessary. The 2017 resolution clarified the case-specific appeal route and the conditions for lifting the restraint; the Court did not declare a general contraceptive ban.
Facts and context
After Imbong v. Ochoa upheld most of the Reproductive Health Law while invalidating specified provisions, ALFI and other petitioners questioned how the FDA was implementing the Court’s requirements for contraceptive products. They submitted oppositions to applications for recertification and also challenged products with existing registrations.
The FDA issued certificates for Implanon and Implanon NXT despite the pending objections. The petitioners said requests for information, consideration of their opposition, and a hearing remained unanswered. They sought judicial relief against certification and distribution, together with a separate contempt petition.
The dispute involved the procedure for evaluating contested scientific claims under the RH Law. The FDA and DOH maintained that certification was regulatory work within the agency’s expertise and did not require the process demanded by the petitioners. A temporary restraining order was issued while the controversy was pending.
Issue
Could the FDA approve the challenged products without meaningfully considering the oppositions, and what process and remedy did the Court require after its 2017 clarification?
Ruling and doctrine
In its August 24, 2016 decision, the Supreme Court remanded the controversy to the FDA so the oppositions could be considered through a fair administrative process. It directed procedural measures consistent with Imbong and the RH Law. The Court denied the separate contempt petition for lack of a concrete basis.
The April 26, 2017 resolution is essential to understanding the disposition. The Court maintained the requirement of a genuine opportunity to present science-based evidence but clarified that the FDA did not have to conduct a courtroom-style trial. Providing a public-comment mechanism while ignoring the submitted opposition did not satisfy the required process.
The FDA retained responsibility for the scientific evaluation. In this certification context, the Court described substantial evidence through the best scientific evidence available, including systematic reviews, meta-analyses, relevant clinical guidelines, and recommendations of medical organizations. The FDA could seek additional scientific information and expert assistance rather than confining itself to the parties’ submissions. Scientific subject matter and regulatory expertise did not place agency action beyond judicial review for grave abuse of discretion.
The 2017 resolution modified the original appeal direction: in this particular case, an appeal from the FDA’s final resolution was to the Office of the President because the Health Secretary was herself a party. That case-specific instruction should not be converted into a general route for every FDA dispute.
The Court directed the FDA to decide within sixty days after the matter was deemed submitted for resolution. The restraint would be deemed lifted after the required process and an FDA decision finding the questioned products non-abortifacient. The Court did not itself declare the products abortifacients or prohibit all contraceptive supplies.
Practice implications
Parao Law practice guidance
For physicians
- Distinguish the legal rules on patient consent and conscientious objection discussed in Imbong from the FDA’s authorization of a particular product.
- For current use, verify the product’s present FDA authorization and any applicable restrictions. A historical restraining order is not a current registration check.
- Use evidence appropriate to the product and question. A contested assertion about mechanism of action should be evaluated against the scientific and regulatory record.
For lawyers
- Read the 2016 decision with the 2017 resolution. Identify the product, application, opposition, evidence actually considered, and final administrative disposition.
- A due-process objection should identify the lost opportunity to participate or the material evidence ignored; it need not presume entitlement to a full trial in the agency.
- Confirm the available administrative remedy and proper appeal route for the present matter. The Court’s direct-to-Office-of-the-President instruction reflected the parties in this litigation.
Limits of the ruling
These decisions concern a defined certification controversy and its historical orders. They do not determine the current registration of any contraceptive product or establish a nationwide continuing ban. The remand required the FDA to decide the scientific questions through a lawful process, not to adopt the petitioners’ scientific claims as established fact.
Official sources
Read the full decision ↗For general information. The full decision and later developments should be considered when applying a ruling to a particular matter.